Pharmena S.A.

Warsaw Stock Exchange PHR.WA

Pharmena S.A. Total Non-Current Liabilities for the year ending December 31, 2023: USD 34.23 K

Pharmena S.A. Total Non-Current Liabilities is USD 34.23 K for the year ending December 31, 2023, a -93.75% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Pharmena S.A. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 548.00 K, a -52.81% change year over year.
  • Pharmena S.A. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 1.16 M, a 2,560.87% change year over year.
  • Pharmena S.A. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 43.64 K, a -29.73% change year over year.
  • Pharmena S.A. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 62.10 K, a 281.36% change year over year.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
Warsaw Stock Exchange: PHR.WA

Pharmena S.A.

CEO Mr. Konrad Palka
IPO Date Aug. 1, 2008
Location Poland
Headquarters ul. Wólczanska 178
Employees 15
Sector Health Care
Industries
Pharmaceuticals Biotechnology Cosmetics
Description

Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including skin, hair, and nail care products, as well as dietary supplement for atherosclerosis prophylaxis. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. The company is developing 1-MNA, an anti-atherosclerosis drug which is under phase II clinical trial. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.

StockViz Staff

January 15, 2025

Any question? Send us an email